Bronchiectasis Pipeline Review, H1 2018 [Report Updated: 24042018] Prices from USD $2000

04:43 EDT 12 Aug 2018 | BioPortfolio Reports

Bronchiectasis Pipeline Review, H1 2018


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis Pipeline Review, H1 2018, provides an overview of the Bronchiectasis Respiratory pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis CF bronchiectasis and nonCF bronchiectasis.

Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bronchiectasis Respiratory, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis Respiratory pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 3 respectively.

Bronchiectasis Respiratory pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis Respiratory.

The pipeline guide reviews pipeline therapeutics for Bronchiectasis Respiratory by companies and universities/research institutes based on information derived from company and industryspecific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.

The pipeline guide reviews key companies involved in Bronchiectasis Respiratory therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bronchiectasis Respiratory therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis Respiratory

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.

Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bronchiectasis Respiratory.

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bronchiectasis Respiratory pipeline depth and focus of Indication therapeutics.

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Original Article: Bronchiectasis Pipeline Review, H1 2018 [Report Updated: 24042018] Prices from USD $2000


More From BioPortfolio on "Bronchiectasis Pipeline Review, H1 2018 [Report Updated: 24042018] Prices from USD $2000"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...